[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ConvaTec Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":143},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,72,99,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100626693","a-study-on-the-efficacy-and-safety-of-a-nitric-oxide-generating-dressing-in-the-treatment-of-diabetes-related-foot-ulcers-100626693",false,"NCT07438951","A Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing in the Treatment of Diabetes Related Foot Ulcers.","A Prospective, Multi-Centre, Observational, Real World Evidence Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing (ConvaNiox™) in the Treatment of Diabetes Related Foot Ulcers (DFUs).","ONWARD","Inclusion Criteria:\n\nIC-1 - Subjects at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study\n\nIC-2 - The subject must have either type 1 or type 2 diabetes and a diabetes-related ulcer meeting all the following characteristics:\n\nIC-2a Classified as University of Texas (UT) Classification Grade 1 stages A-D IC-2b At or below the level of malleolus IC-2c Neuropathic or neuroischemic etiology confirmed through Electronic Medical Records (EMR) IC-2d Ulcer surface area between ≥1 and ≤25 cm² IC-2e For subjects who have more than one ulcer, the largest ulcer will be the study ulcer\n\nIC-3 Non-infected and infected ulcers are eligible for inclusion, with infection being classified using the International Working Group on the Diabetic Foot (IWGDF) Infection guidelines.\n\nOnly PEDIS 2 infections are permitted - Mild superficial skin and soft tissue infections with no systemic manifestations and involving:\n\n• Erythema extending ≥2 cm from the wound margin, and\u002For tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone)\n\nIC-4 Adequate arterial supply in the lower extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grade 0-1;\n\n1. Palpable foot pulse with biphasic or triphasic pedal Doppler waveforms, AND\n2. Ankle Brachial Index (ABI) \\>0.6 OR Toe Brachial Index (TBI) \\>0.5, OR\n3. Toe pressure \\>40mmHg\n\nExclusion Criteria:\n\nEC-1 Ulcers that are tunnelling or have cavities (\\>10mm in depth)\n\nEC-2 An ulcer that is actively bleeding. Subjects may be re-screened once active bleeding has stopped\n\nEC-3 Subjects taking any medication known to inhibit wound closure including chemotherapy and immunomodulatory biological agents. The use of systemic corticosteroids \\\u003C10mg\u002Fkg\u002Fday is permitted\n\nEC-4 Active Charcot foot","ALL","18 Years",{"count":20,"type":21},102,"ESTIMATED","OBSERVATIONAL","Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment of diabetic foot ulcers",[25],"Diabetic Foot Ulcers (DFUs)",[27,28,29,30,31],"Diabetic foot ulcers","Nitric Oxide","Wound","dressing","Woundcare","NOT_YET_RECRUITING","2026-03-16",{"date":35,"type":36},"2026-03-18","ACTUAL",{"date":38,"type":21},"2026-07",{"date":40,"type":21},"2027-09",{"name":42,"class":43},"ConvaTec Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100619240","convavac-ag-negative-pressure-wound-therapy-system-in-chronic-wounds-100619240","NCT07342049","ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds","A Study to Determine the Safety and Performance of ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds","ConvaVAC VLU","Inclusion Criteria:\n\n* A wound which is amenable to NPWT and is a VLU as defined by CEAP Classification of C6 or C6R\n* Wounds that are clean or contaminated\n* Wounds with at least one sign or symptom of infection\n* Wounds that in the opinion of the investigator would benefit from an antimicrobial dressing\n* ≥18 years old at the time of consent\n\nExclusion Criteria:\n\n* Known sensitivities or allergies to components of the ConvaVAC™ Ag+ NPWT System\n* Ischemic wounds with necrotic tissue or eschar present that require sharp debridement\n* Wound is too small or too large based on wound dressing size (\\> 0.5cm2 and \\\u003C 100cm2)\n* Wound depth \\>7cm\n* Wounds requiring concomitant use of DuoDERM® gel, hydrogels, petroleum-based creams\u002F ointment-\u002Fgels per the opinion of the investigator\n* Active chemotherapy, radiation therapy, or immunotherapy for cancer or completed treatment within the last 3 months\n* Any active malignancy at site of dressing application\n* Exposed bone in target wound\n* Exposed blood vessels or nerves in target wound\n* Systemic infection and\u002For systemic inflammatory response syndrome (SIRS), sepsis\n* Cellulitis in target wound\n* Untreated deep tissue infection including but not limited to osteomyelitis, septic arthritis\n* Active Pregnancy\n* Subjects that in the opinion of the investigator are not suitable for enrollment\n* Vulnerable subjects as determined by ICH Harmonized Guideline, Good Clinical Practice E6(R2)",{"count":53,"type":21},87,"INTERVENTIONAL",[56],"NA","Purpose of this study is to learn more about how safe and effective the ConvaVAC™ Ag+ wound therapy system is in treating certain types of long-lasting wounds, called chronic wounds. In this study, the focus is on Venous Leg Ulcers (VLUs). Chronic wounds are wounds that do not heal properly or take a long time to heal. They can cause pain, discomfort, and affect your day-to-day life. These types of wounds are also challenging for healthcare teams to treat and can take up a lot of healthcare resources. Venous Leg Ulcers (VLUs) are the most common type of chronic leg wound and affect about 1 in every 100 people. Usual treatments for VLUs include cleaning the wound, using special dressings, applying pressure (compression therapy), and sometimes using creams or dressings that contain silver to fight infection. This study is being done to see if the wound therapy system can help heal venous leg ulcers more effectively and safely.",[59],"Venous Leg Ulcer (VLU)",[61,62,63],"Venous Leg Ulcer","Negative Pressure Wound Therapy","Silver ions","2026-01-28",{"date":66,"type":36},"2026-01-29",{"date":68,"type":21},"2026-01-12",{"date":70,"type":21},"2026-10-01",{"name":42,"class":43},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100609038","edx110-randomized-control-trial-for-treatment-of-dfus-100609038","NCT07209358","EDX110 Randomized Control Trial for Treatment of DFUs","A Multi-Centre, Observer-Blinded, Randomized Controlled Trial of EDX110 for the Treatment of Diabetic Foot Ulcers","Inclusion Criteria:\n\n* Participants at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study.\n* The participant must have an index ulcer meeting the following characteristics:\n\n  1. Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory.\n  2. Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue.\n  3. Located on the anatomical foot; defined as distal to the medial or lateral malleolus.\n* Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema \\>0.5 but \\\u003C2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge.\n* Ulcer duration at randomization must be present for ≥1 month but less than \\\u003C24 months in duration.\n* Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2.\n* If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:\n\n  1. The ulcer with the largest wound area, as long as it meets all other criteria.\n  2. ≥3cm distance from any other ulcer on the affected limb\n* Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history).\n* HgbA1c \\\u003C12% (NGSP) OR 108 mmol\u002Fmol (IFCC) OR average blood glucose 298 mg\u002FDL.\n* Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD).\n* Participants are required to have either.\n\n  1. Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5\n  2. OR Dorsum transcutaneous oxygen test (TcPO2): \\>40 mm\u002FHg\n\nExclusion Criteria:\n\n* Participants with wounds that have any of the following characteristics:\n\n  1. Wagner Grade 2 - ulcers extend into tendon, bone, or capsule\n  2. Grade 3 - deep ulcer with osteomyelitis, or abscess\n  3. Grade 4 - partial foot gangrene\n  4. Grade 5 - whole foot gangrene\n* Infections that are classified as:\n\n  1. PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and\u002For tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone).\n  2. PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome \\[SIRS\\]).\n  3. In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture\u002Fhistopathology of a bone specimen\n  4. OR Cellulitis\u002Flymphangitis\u002Fsoft tissue gas or necrotizing fasciitis originating from the wound site.\n* Tunnelling, Cavity or undermining wounds.\n* Known or suspected local skin malignancy at the site of the ulcer.\n* A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis).\n* Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities.\n* Active Charcot deformity.\n* Wound duration \\>2 years.\n* Participants receiving any of the following prior therapies. In the last 30 days:\n\n  1. Has required systemic corticosteroids \\>10mg\u002Fkg\u002Fday OR\n  2. Participant has required Chemoradiation (chemotherapy and\u002For radiation therapy) to treat cancer and is immunocompromised OR\n  3. Participant is anticipated to require such medications during the study period.\n  4. Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix).\n  5. Has undergone any amputation to the affected leg.\n* Known hypersensitivity to constituents of the product.\n* Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator.\n* Women of childbearing age (women aged \\\u003C55 years who have not undergone menopause) who are:\n\n  1. Pregnant at time of enrolment\n  2. Breast-feeding\n* Concurrent enrolment in any other study.","90 Years",{"count":81,"type":21},298,[56],"Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.",[85,86],"Wound Heal","Diabetic Foot Ulcer",[88],"Hard to heal wounds","RECRUITING","2025-12-15",{"date":92,"type":36},"2025-12-17",{"date":94,"type":36},"2025-10-30",{"date":96,"type":21},"2026-12-31",{"name":42,"class":43},4,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":54,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100562672","innoven-efficacy-of-porcine-placental-extracellular-matrix-plus-standard-of-care-soc-versus-soc-alone-100562672","NCT06606210","INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone","An Observer-Blinded Multicenter Randomized Controlled Trial Evaluating Porcine Placental Extracellular Matrix as an Adjunct to Standard of Care Versus Standard of Care Alone in Hard-to-Heal Venous Leg Ulcers","Inclusion Criteria:\n\n1. Subjects must be at least 21 years of age or older.\n2. At randomization subjects must have a target ulcer with a minimum surface area of 1 cm2 and a maximum surface area of 25 cm2 measured post-debridement.\n3. The target ulcer must have been present for a minimum of 4 weeks and cannot have received more than 52 weeks of high-level compression prior to the initial screening visit.\n4. No visible signs of improvement in the four weeks prior to randomization: less than 40% reduction in wound size over the 4 weeks prior to randomization.\n5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and ≤ 1.3;\n   2. TBI ≥ 0.6;\n   3. TCOM ≥ 40 mmHg;\n   4. PVR: biphasic.\n6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n7. The potential subject must agree to attend the weekly study visits required by the protocol.\n8. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 6 months.\n2. The target ulcer exhibits signs or symptoms consistent with clinical infection, requiring topical antibiotic or antimicrobial agents or systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n3. The target ulcer exposes tendon or bone.\n4. There is evidence of osteomyelitis complicating the target ulcer.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the Principal Investigator believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Digital planimetry is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. The potential subject has had a lower extremity Deep Vein Thrombosis (DVT) to either limb within the previous 90 days.\n11. The potential subject is unable to tolerate therapeutic compression (30-40mmHg).\n12. Women who are pregnant or considering becoming pregnant within the next 6 months.\n13. The potential subject has end stage renal disease requiring dialysis.\n14. Participation in another clinical trial involving treatment with an investigational product within the previous 30 days.\n15. A potential subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n16. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n17. The potential subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n18. Potential subjects with a sensitivity or allergy to porcine materials or collagen.\n19. Potential subjects with religious or personal objection to use of porcine- or animal-derived materials.\n20. A subject with a disorder that would create unacceptable risk of treatment complications.","21 Years",{"count":108,"type":21},120,[56],"INNOVEN is a multi-center randomized controlled clinical trial to evaluate the efficacy of porcine placental extracellular matrix (PPECM) and standard of care (SOC) versus SOC alone in the closure of non-healing venous leg ulcers (VLUs).",[85,61],"2025-08-21",{"date":114,"type":36},"2025-08-22",{"date":116,"type":36},"2024-09-19",{"date":118,"type":21},"2026-04",{"name":42,"class":43},1,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":54,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":142},"100563490","ideal-efficacy-of-porcine-placental-extracellular-matrix-augmented-plus-standard-of-care-soc-versus-soc-alone-for-the-management-of-diabetic-foot-ulcers-100563490","NCT06616844","IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers","Evaluating the Efficacy of Porcine Placental Extracellular Matrix Augmented Wound Care Against Standard Wound Care for the Management of Diabetic Foot Ulcers: A Multi-center, Prospective, Observer-blinded, Randomized Controlled Clinical Trial.","IDEAL","Inclusion:\n\n1. Subjects at least 21 years old. At least 50% of the enrolled population must be \\> 65 years of age.\n2. Known history of type 1 or type 2 diabetes.\n3. The patient must have a target ulcer meeting the following characteristics:\n\n   i. A diabetic ulcer that is either Wagner Grade 1 or Wagner Grade 2 . ii. Located on the anatomical foot; defined as a minimum of 50% of ulcer area extending distal to the medial malleolus.\n\n   iii. The target ulcer must have been present for a minimum of 4 weeks and no longer than 52 weeks.\n\n   iv. The target ulcer must display evidence of delayed wound healing, defined as less than 50% wound area reduction over the four weeks preceding randomization.\n\n   v. At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post-debridement.\n4. If two or more diabetic foot ulcers with the same Wagner Grade are present, the Index ulcer must additionally be:\n\n   i. the ulcer with the largest wound area; ii. ≥ 2cm distant from any other ulcer on the affected limb, post-debridement; iii. the only ulcer to be evaluated by the study (one patient, one wound).\n5. Subject has adequate circulation to the affected extremity, as demonstrated by at least one of the following within the past 30 days i. ABI ≥ 0.7 and ≤ 1.3; ii. TBI ≥ 0.6; iii. TCOM ≥ 40 mmHg; iv. PVR: biphasic.\n6. BMI ≤45\n7. Subject is willing to participate in all procedures and follow-up evaluations necessary to complete the study.\n8. Subject has signed informed consent.\n\nExclusion:\n\n1. The potential subject is known to have a life expectancy of \\<6 months.\n2. Index Ulcers will be excluded if they meet any of the following criteria upon assessment:\n\n   i. Index ulcer determined to be due to a condition other than diabetes ii. Active Charcot deformity OR major structural abnormalities of the foot iii. Known or suspected local skin malignancy to the index diabetic ulcer iv. Wound duration \\>12 months without intermittent closure\n3. The target ulcer exhibits 2 or more of the following signs or symptoms consistent with clinical infection:\n\n   i. erythema that extends ≥ 0.5cm from wound edge ii. local increased warmth iii. purulent exudate iv. local swelling or induration v. local tenderness or pain\n4. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator\\'s exam or radiographic evidence.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent), radiation therapy, cytotoxic chemotherapy, or is taking medications that the Principal Investigator believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer, as measured by digital planimetry or manual linear measurements (e.g. with a ruler), decreases by more than 25% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period).\n9. The surface area of the target ulcer, as measured by digital planimetry, decreases by more than 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. The potential subject is unable to adhere to therapeutic offloading, if required by anatomical location of target ulce.\n11. Women who are pregnant or considering becoming pregnant within the next 6 months.\n12. The potential subject has end stage renal disease requiring dialysis.\n13. Participation in another clinical trial involving treatment with an investigational product within the previous 30 days.\n14. A potential subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n15. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n16. The potential subject has a malnutrition indicator score \\<17 as measured on the Mini Nutritional Assessment.\n17. Potential subjects with a sensitivity or allergy to porcine materials or collagen will be excluded.\n18. Potential subjects with religious or personal objection to use of porcine- or animal-derived materials will be excluded.\n19. A subject with a disorder that would create unacceptable risk of treatment complications is excluded.\n20. Subjects will be considered ineligible for enrolment if any of the following criteria are met:\n\n    i. Immune system disorders including Systemic Lupus Erythematosus (SLE), Acquired Immunodeficiency Syndrome (AIDS) or HIV.\n\n    ii. In the past 6 months, having undergone a revascularization procedure aimed at increasing blood flow in the target limb OR any amputation affecting the target limb",{"count":130,"type":21},194,[56],"A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.",[85,134],"Ulcer","2025-05-16",{"date":137,"type":36},"2025-05-21",{"date":139,"type":36},"2025-02-12",{"date":38,"type":21},{"name":42,"class":43},9,""]